Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01740089
Other study ID # PEG-IFN?-2
Secondary ID
Status Completed
Phase Phase 2/Phase 3
First received November 30, 2012
Last updated July 22, 2015
Start date November 2011
Est. completion date December 2013

Study information

Verified date July 2015
Source Biocad
Contact n/a
Is FDA regulated No
Health authority Russia: Ministry of Health of the Russian Federation
Study type Interventional

Clinical Trial Summary

The purpose of the study is to demonstrate the noninferiority of Algeron 1.5 and 2.0 μg/kg/week in combination with ribavirin compared to PegIntron in combination with ribavirin in the treatment of chronic hepatitis C, and to determine therapeutic dose of Algeron.


Description:

After 12 weeks of treatment, an assessment of treatment efficacy was performed, i.e. rates of rapid (after 4 weeks) and early (after 12 weeks) virologic responses according to serum HCV RNA level PCR data. In patients without virologic response after 12 weeks, AVT was discontinued, and they were withdrawn from the study. Patients with EVR were enrolled in a follow-up period. During the follow-up period, patients of the first and the second group will receive Algeron in the selected therapeutic dose in combination with ribavirin, patients of the third group - PegIntron in combination with ribavirin during 12 or 36 weeks (depending on a genotype of the virus), afterwards they will be followed up without therapy for 24 weeks.


Recruitment information / eligibility

Status Completed
Enrollment 150
Est. completion date December 2013
Est. primary completion date July 2012
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 70 Years
Eligibility Inclusion Criteria:

1. Signed informed consent to participate in the study.

2. Hepatitis ? virus infection (genotypes 1?, 1b, 2, 3, 4) confirmed by a positive quantitative PCR (HCV RNA > 50 IU/ml).

3. Males and females aged from 18 to 70 years inclusive.

4. Body mass index of 18 - 30 kg/m inclusive.

5. Increased ALT level (> 40, < 400 IU/L), documented at least twice within the last 6 months.

6. Preserved protein synthetic liver function (i.e. INR < 1.7, albumin > 35 g/l).

7. No signs of hepatic encephalopathy or abdominal fluid retention according to clinical and ultrasound examination.

8. Fertile patients and their partners agree to use barrier contraception throughout the study and 7 months after its completion.

Exclusion Criteria:

1. Intolerance of IFN alpha formulations, ribavirin or any components of these drugs according to the past medical history.

2. Infection by hepatitis B virus or HIV.

3. Past history of HCV treatment with IFN alfa or pegylated IFN alfa formulations.

4. Administration of interferons and/or interferon inducing drugs for any indication within 1 month prior to the enrollment into the study.

5. Cholestatic hepatitis (conjugated bilirubin, alkaline phosphatase, ALT levels of more than 5 ULN).

6. Decompensated liver cirrhosis confirmed by laboratory findings (Child-Pugh class B, ?) or ultrasound examination.

7. Any documented autoimmune diseases.

8. Hematologic (hemoglobin < 130 g/L for males and < 120 g/L for females; neutrophils < 1.5 ?109/L; platelets < 90 ?109/L) or biochemical abnormalities (creatinine level of more than 1.5 ULN, creatinine clearance less than 50 mL/min).

9. Documented diagnosis of hemoglobinopathies (e.g., thalassemia major, sickle-cell anemia).

10. Heavy depression, any other mental disorders, which in the Investigator's opinion can be contraindications for antiviral treatment.

11. Epilepsy and/or other functional disorders of the central nervous system.

12. Abnormal thyroid function (TTH level beyond the normal values).

13. Malignant neoplasms.

14. Pregnancy, lactation period.

15. Severe comorbidities (for example, severe hypertension, severe coronary heart disease, decompensated diabetes mellitus), which in the Investigator's opinion can be contraindications for antiviral treatment.

16. Documented rare hereditary diseases, such as intolerance of lactose, sucrose, fructose, lactase deficiency or glucose-galactose malabsorption.

17. Current alcohol or drug abuse, which in the Investigator's opinion can be contraindications for antiviral treatment or restrict treatment compliance.

18. Simultaneous participation in other clinical trials or prior participation in this or another clinical trial within less than 30 days after its completion.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Drug:
Algeron
1.5 µg/kg or 2.0 µg/kg of body weight weekly subcutaneously
PegIntron
1.5 µg/kg/week subcutaneously in combination with ribavirin
Ribavirin
800-1400 mg/day orally

Locations

Country Name City State
Russian Federation Moscow State University of Medicine and Dentistry Moscow

Sponsors (1)

Lead Sponsor Collaborator
Biocad

Country where clinical trial is conducted

Russian Federation, 

Outcome

Type Measure Description Time frame Safety issue
Other Immunogenicity Number of randomized patients with neutralizing antibodies to IFN alfa on weeks 0, 12, 24, 48 (for patients with genotype 1 or 4) and 24 weeks after last dose of study treatment. Weeks 0, 12, 24, 48 (for patients with genotype 1 or 4) and 24 weeks after last dose of study treatment No
Primary Number of Randomized Patients Achieving Early Virologic Response (EVR) - Negative PCR Result for HCV RNA (< 15 IU/ml) or = 2log10 Decrease of Viral Load After 12 Weeks of Study Treatment. 12 weeks Yes
Secondary Number of Randomized Patients Achieving Rapid Virologic Response (RVR) - Negative PCR Result for HCV RNA (< 15 IU/ml) After 4 Weeks of Treatment. 4 weeks Yes
Secondary Number of Randomized Patients Achieving Sustained Virologic Response (SVR) - Negative PCR Result for HCV RNA (< 15 IU/ml) 24 Weeks After Last Dose of Study Treatment. 24 weeks after last dose of study treatment Yes
Secondary Number of Patients Who Have Undetectable HCV RNA (< 15 IU/ml) at the End of Treatment. After 24 weeks of treatment for patients with genotype 2 or 3 and after 48 weeks of treatment for patients with genotype 1 or 4. Yes
See also
  Status Clinical Trial Phase
Completed NCT03686722 - Effect of Co-administration of Metformin and Daclatasvir on the Pharmacokinetis and Pharmacodynamics of Metformin Phase 1
Recruiting NCT04510246 - Link Hepatitis C Notifications to Treatment in Tasmania N/A
Completed NCT03413696 - Effects of Health Literacy and HCV Knowledge on HCV Treatment Willingness in HIV-coinfected Patients
Completed NCT03109457 - Hepatitis C Virus Detection in Oral Squamous Cell Carcinoma
Completed NCT03118674 - Harvoni Treatment Porphyria Cutanea Tarda Phase 2
Completed NCT01458054 - Effect of Omeprazole and Ritonavir on GSK2336805 Pharmacokinetics in Healthy Adults Phase 1
Completed NCT03740230 - An Observational Study of Maviret (Glecaprevir/Pibrentasvir) for Korean Chronic Hepatitis C Genotypes 1 to 6 Patients According to the Standard for Re-examination of New Drugs
Completed NCT03426787 - Helping Empower Liver and Kidney Patients N/A
Completed NCT03627299 - Renal Transplants in Hepatitis C Negative Recipients With Nucleic Acid Positive Donors Phase 4
Completed NCT00006301 - Immune Response to Hepatitis C Virus
Active, not recruiting NCT03949764 - The Kentucky Viral Hepatitis Treatment Study Phase 4
Completed NCT03365635 - Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C Phase 4
Recruiting NCT04405024 - Pilot Study on the Feasibility of Systematic Hepatitis C Screening of Hospitalized Patients N/A
Completed NCT04525690 - Improving Inpatient Screening for Hepatitis C N/A
Completed NCT04033887 - Evaluation Study of RDTs Detecting Antibodies Against HCV
Withdrawn NCT04546802 - HepATocellular Cancer Hcv Therapy Study Phase 3
Active, not recruiting NCT02961426 - Strategic Transformation of the Market of HCV Treatments Phase 2/Phase 3
Completed NCT02705534 - Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 Phase 3
Completed NCT02992184 - PoC-HCV Genedrive Viral Detection Assay Validation Study N/A
Completed NCT02683005 - Study of Hepatitis C Treatment During Pregnancy Phase 1